Blocking the endogenous CRHR2 agonist during gestation induces a mild glucose intolerance rather than overt gestational diabetes suggesting that UCN2 may act in concert with other placental signals to fine-tune the compensatory β-cell adaptations to maternal insulin resistance during pregnancy. The gene discussed is INS; the disease is Glucose intolerance.